TAVI for Native Aortic Valve Regurgitation

Jian (James) Ye, MD, FRCSC Clinical Professor Division of Cardiac Surgery St. Paul's Hospital and Vancouver General Hospital University of British Columbia, Vancouver, Canada

AP VALVES, August 17-19, 2016



Centre for Heart Valve Innovation St. Paul's Hospital, Vancouver





Disclosure Statement of Financial Interest

Consultant: - Edwards Lifesciences - JC Medical Inc.

Causes of aortic regurgitation

Aortic cusp abnormalities . Aortic root abnormalities


- Perforation (eg. infective endocarditis)
- Cusp shrinkage
 - Rheumatic disease
 - Rheumatoid disease
 - Ankylosing spondylitis
- Bicuspid aartic valve

Loss of commissural support

- Ventricular septal defect
- Dissection (tears) of the aorta

- Dilatation
 - Marfan syndrome
 - Familial conditions
 - Ehlers-Danlos syndrome
 - Pseudoxanthomaelasticum
 Idiopathic
- Distortion (aprtitis)
 - Syphils.
 - Rheumatord arthritis
 - Ankylosing spondylitis
 - Nonspecific aortos
 - Dissecting hematoma

Survival in Patients with Asymptomatic Al



Copyright © 2005 by Elsevier Inc.

Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., Õ ûÀ í fengqz 2005

Natural History of Al


TABLE 57-11 -- Natural History of Aortic Regurgitation

Asymptomatic Patients with Normal LV Systolic Function	
Progression to symptoms and or LV dysfunction	<6%/yr
Progression to asymptomatic LV dysfunction	<3.5%/yr
Sudden death	<0.2%/yr
Asymptomatic Patients with LV Systolic Dysfunction	
Progression to cardiac symptoms	>25%/yr
Symptomatic Patients	
Mortality rate	>10%/yr

LV = left ventricular.

From Bonow RO, Carabello B, de Leon AC Jr, et al: ACC/AHA guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 32:1486, 1988.


Survival in Patients with Al



Copyright © 2005 by Elsevier Inc.

Survival without surgery in 242 patients with chronic aortic regurgitation Dujardin KS, et al. Circulation 99:1851, 1999

TAVI for AI









- JenaValve's unique "3-feeler element" allows the clinician to accurately position the
 prosthesis in the anatomically correct position during implantation thus ensuring a precise
 sub-coronary alignment within the patient's native valve.
- JenaClipTM anchoring and clipping mechanism allows the patient's native valve leaflets to be clipped onto the valve enabling the JenaValve to be firmly anchored in the correct anatomical position and provide active fixation and resistance to migration.

CE Mark approval for high risk AI patients


Positioning of 3 Feelers




Deployment of LV Side of Valve




Deployment of Aortic Side of Valve




Aortogram and Echo






J-ValveTM Ausper System Jie-Cheng Medical Technology



J-Valve for Al



J-Valve for Al



Clinical Trial (China)

Characteristic	N=107
Age (years)	74.4 ± 5.2
Male (%)	54.2%
EuroSCORE (%)	27.5 ± 8.3
NYHA Class III or IV (%)	97.2
Cerebravascular disease (%)	6.5
PVD (%)	52.3
CAD (%)	18.7
Prior CABG (%)	1.9
Atrial fibrillation (%)	19.6
DM (%)	15.0



All Cause Mortality	All patients N=107 (64 AS and 43 AI)	
Intraoperative death (%)	0	
30-day mortality (%)	4.67	
6-month mortality (%)	5.65	
12-month Mortality (%)	5.65	

Complications

Complications	30 days	12 months
CVA (%)	0	3.1
MI (%)	0	0
Acute kidney injury (%)	1.0	n/a
Pacemaker(%)	2.8	4.3
Reoperation(%)	0.9	2.4



